Mach7 Technologies Limited announced that Mr. Damien Lim will transition from the role of Chair of the Board to non-executive Director. Mr. David Chambers, presently a non-executive director of Mach7, will be appointed to the role of Chair. In addition, Mr. Mike Lampron, who was appointed as interim CEO on 11 March 2019, will be appointed to the Board as Managing Director. These changes are effective from 24 June 2019. The change in the role of Chair is the first step of a planned board renewal process. The Board continues to assess its composition to ensure it has the appropriate mix of skills, experience and diversity best suited to Mach7. As part of the Board's most recent assessment, it has determined that it will conduct a search for a new director who has deep healthcare/I.T. experience to join the Mach7 Board. The timing for this appointment is planned for later this year. The Board is also welcomed Mr. Lampron to the Board and officially appoint him as Managing Director of Mach7. Mr. Chambers brings extensive global healthcare/I.T. industry experience to the Board. He was previously CEO of Promedicus and has held senior management positions with Nasdaq-listed companies. Mr. Chambers joined the Mach7 Board on 3 August 2018.